Asthma and COPID:: differences and similarities -: With special reference to the usefulness of budesonide/formoterol in a single inhaler (Symbicort®) in both diseases

被引:9
作者
Decramer, M
Selroos, O
机构
[1] Katholieke Univ Leuven, UZ Gasthuisberg, Div Resp, B-3000 Louvain, Belgium
[2] Div Resp, Lund, Sweden
关键词
asthma; COPD; budesonide; formoterol; comparison;
D O I
10.1111/j.1368-5031.2005.00509.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Asthma and chronic obstructive pulmonary disease (COPD) both have a high prevalence worldwide and yet each condition remains underdiagnosed. Despite a number of common features, these inflammatory respiratory syndromes have distinct clinical outcomes. COPD represents a greater economic burden than asthma because it has a less favourable prognosis and is associated with greater morbidity and mortality. Therefore, it is important to distinguish between these two diseases at an early stage, so that appropriate therapy can be prescribed to prevent deterioration. However, effective treatments that may be used in both conditions can minimise the effects of misdiagnosis and maximise the impact of treatment without the associated complexity when both conditions occur together. The current review summarises the differences and similarities of asthma and COPD, in terms of risk factors, pathophysiology, symptoms and diagnosis, to provide greater understanding of the role of budesonide/ formoterol in a single inhaler in both diseases.
引用
收藏
页码:385 / 398
页数:14
相关论文
共 183 条
[1]   Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma [J].
Aalbers, R ;
Backer, V ;
Kava, TTK ;
Omenaas, ER ;
Sandström, T ;
Jorup, C ;
Welte, T .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (02) :225-240
[2]   Are asthma medications and management related to deaths from asthma? [J].
Abramson, MJ ;
Bailey, MJ ;
Couper, FJ ;
Driver, JS ;
Drummer, OH ;
Forbes, AB ;
McNeil, JJ ;
Walters, EH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (01) :12-18
[3]   Inhaled and systemic corticosteroid therapies: Do they contribute to inspiratory muscle weakness in asthma? [J].
Akkoca, O ;
Mungan, D ;
Karabiyikoglu, G ;
Misirligil, Z .
RESPIRATION, 1999, 66 (04) :332-337
[4]   The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials [J].
Alsaeedi, A ;
Sin, DD ;
McAlister, FA .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (01) :59-65
[5]  
Altose MD, 2000, NEW ENGL J MED, V343, P1902
[6]   PI SZ phenotype in chronic obstructive pulmonary disease [J].
AlvarezGranda, L ;
CaberoPerez, MJ ;
BustamanteRuiz, A ;
GonzalezLamuno, D ;
DelgadoRodriguez, M ;
GarciaFuentes, M .
THORAX, 1997, 52 (07) :659-661
[7]   The costs of exacerbations in chronic obstructive pulmonary disease (COPD) [J].
Andersson, F ;
Borg, S ;
Jansson, SA ;
Jonsson, AC ;
Ericsson, Å ;
Prütz, C ;
Rönmark, E ;
Lundbäck, B .
RESPIRATORY MEDICINE, 2002, 96 (09) :700-708
[8]  
*ASS ASTHM ALL, 2002, OCC ASTHM DIC ALL
[9]   Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction [J].
Au, DH ;
Curtis, JR ;
Every, NR ;
McDonell, MB ;
Fihn, SD .
CHEST, 2002, 121 (03) :846-851
[10]   Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma [J].
Aubier, M ;
Pieters, WR ;
Schlösser, NJJ ;
Steinmetz, KO .
RESPIRATORY MEDICINE, 1999, 93 (12) :876-884